Dutch investment company Prosus announced Wednesday that it has poured $460 million into French health technology startup Alan, giving the company a valuation of $6.3 billion.
Alan currently operates across four countries — France, Canada, Belgium, and Spain — offering services that include health insurance and telehealth. Through the first quarter of 2026, the company reported annual recurring revenue of 800 million euros, equivalent to roughly $909 million.
The investment is structured as a combination of primary and secondary equity. According to the company, the funds are intended to fuel Alan’s growth in international markets and speed up the development of artificial intelligence-driven products.
As part of the deal, Prosus will also give Alan access to its Large Commerce Model, a resource that could further support the startup’s expansion efforts.
The transaction has not yet been finalized. Closing the deal will require regulatory clearance from the appropriate authorities, including oversight bodies in France.
(Currency conversion note: $1 = 0.8800 euros at time of reporting)
